ライフサイエンスコーパス: limited success

1 Limited success in the clinical management and a persist

2 Limited success of previous genetics studies may be attr

3 Limited successes in P450 3A4 active-site structure stud

4 Limited successes of gene finding for major depressive d

5 or PVR is surgical intervention, which has a limited success rate that diminishes in patients with re

6 uctures using high frequencies, but achieved limited success.

7 ploitation as a clinical target has achieved limited success and novel molecular targets are required

8 tion targeting the PI3K pathway has achieved limited success due to the intricate balance of its diff

9 ast growth factor (FGF) family, has achieved limited success in protein formulations.

10 unity-based screening programs have achieved limited success due to lack of follow-up of screened pat

11 us (HPV)-16 E6 and E7 proteins have achieved limited success in HPV-positive oropharyngeal cancer (OP

12 n using extracorporeal systems have achieved limited success.

13 Cancer vaccine therapies have only achieved limited success when focusing on effector immunity with

14 servation subsidy schemes have only achieved limited success.

15 Although limited success was achieved, these studies established

16 ut the small number of affected families and limited success in validating candidates have impeded ge

17 Until recently, there had been limited success in identifying the specific genetic vari

18 ies in clinical applications, there has been limited success in extending engineered RNA devices to m

19 possible in all patients and there has been limited success in generating TIL in other cancers.

20 or depressive disorder (MDD), there has been limited success in identifying replicable genetic risk l

21 a model polygenic trait, but there has been limited success in identifying the genes underlying its

22 While there has been limited success in inhibiting the protein directly, phas

23 and speed of identification, there has been limited success in the efforts that have been made to mo

24 ve in the treatment of GISTs, there has been limited success in the treatment of mastocytosis.

25 rs work to understand cancer, there has been limited success to effectively combine forces and collab

26 s of men in the US, however, there have been limited successes so far in its therapy.

27 nhibit T cell proliferation has only brought limited success in adult T cell leukemia/lymphoma (ATL)

28 logical catalysts, or simplified mimics, but limited success has been achieved.

29 therapy has a long history with striking but limited success in patients with melanoma.

30 nase C (PKC) and its involvement in disease, limited success has been attained in the generation of P

31 ave encountered practical challenges and had limited success.

32 through the generation of tissue culture had limited success for Setaria viridis, an emerging C4 mono

33 Although the former had limited success, the role of rare genetic events, such a

34 h threshold for detection have generally had limited success, with high false-positive rates and subt

35 ce using specific inhibitors of P-gp has had limited success and has faced many therapeutic challenge

36 f vaccines based on protein antigens has had limited success because of delivery issues.

37 ne transfer vehicles in this setting has had limited success because of silencing of transgene expres

38 ene therapy using proapoptotic genes has had limited success because the therapy is prone to cause si

39 mic delivery of the TNFalpha protein has had limited success clinically because of severe dose-limiti

40 ignals by sequence homology searches has had limited success due to sequence heterogeneity.

41 Oral immunotherapy has had limited success in establishing tolerance in food allerg

42 s by national governments since 2010 has had limited success in increasing the coverage across differ

43 ving human brain, but this technique has had limited success in tracing pathways into gray matter.

44 irable for various applications, but has had limited success owing to thermodynamic favorability of s

45 n prior to wild population collapses has had limited success, leading to the development of warning s

46 ide effects and less abuse potential has had limited success.

47 ceptibility genes and their variants has had limited success.

48 ute graft-versus-host disease (GVHD) has had limited success.

49 derived modulators of bone formation has had limited success.

50 kidneys for pharmacologic treatment has had limited success.

51 T790M with irreversible inhibitors have had limited success and are associated with toxicity due to

52 lectivity in reactions of this type have had limited success and have not been related to activation

53 These interventions have had limited success and have not systematically incorporated

54 ams aimed at treating heart failure have had limited success and this therapeutic area remains a majo

55 Previous investigations have had limited success and/or require unique environments that

56 trates used to inhibit AGT activity have had limited success because of dose-limiting myelotoxicity.

57 ponent, genetic association studies have had limited success detecting common variants which influenc

58 expression divergence in orthologs have had limited success for two primary reasons.

59 effects of cocaine; however, SSRIs have had limited success in clinical trials for cocaine abuse, po

60 ogeneity, candidate gene approaches have had limited success in finding high-risk alleles in most cas

61 Although case-control SNP-GWAS have had limited success in identifying common genetic variants f

62 molecular genetic analyses to date have had limited success in identifying specific loci responsible

63 Although candidate gene studies have had limited success in identifying susceptibility loci, geno

64 n patients with atrial fibrillation have had limited success in improving guideline adherence.

65 ical and anatomical prognosticators have had limited success in predicting clinical trajectories.

66 orescent protein (GFP)-based probes have had limited success in recording electrical activity of neur

67 revious genetic association studies have had limited success in robustly identifying risk loci.

68 rs; however, leukotriene inhibitors have had limited success in the clinic.

69 mmunogenic, scalable platforms that have had limited success with DNA delivery to the eye.

70 terial or to synthesize it in vitro have had limited success(4-6).

71 inically useful prognostic subtypes have had limited success, a recent report showed that machine-lea

72 cal interventions to prevent stroke have had limited success, but technological developments offer im

73 lesion burden with clinical status have had limited success, however, suggesting that lesion locatio

74 infections among household members have had limited success, likely due to the multiplicity of poten

75 s currently available, such methods have had limited success.

76 orts to reverse this gene silencing have had limited success.

77 improvements in populations' health have had limited success.

78 uman health losses, control efforts have had limited success.

79 restore acidified streams and biota have had limited success.

80 rmount ABC-transporter-mediated MDR have had limited success.

81 primarily on emergency departments have had limited success.

82 ing specific inflammatory mediators have had limited success.

83 hat persist without causing disease have had limited success.

84 with traditional narrowband stimuli have had limited success.

85 l treatments, although widely used, have had limited success.

86 tion, as in the general population, have had limited success.

87 nome-wide association (GWA) studies have had limited success.

88 ify genetic susceptibility variants have had limited success.

89 lar space using electron microscopy have had limited success; however, a biophysical approach based o

90 corporating LP ablation and pace-mapping had limited success in patients with NICM compared with ICM,

91 rected gene therapy approaches have only had limited success in Ppt1(-/-) mice.

92 Triage on the basis of clinical signs had limited success, and the time to diagnosis by quantitati

93 n of persistent atrial fibrillation (AF) has limited success.

94 resectability using noninvasive imaging has limited success, with most patients having metastases at

95 Because treatment often has limited success, new approaches must be identified.

96 nfections and DENV disease pathogenesis, has limited success to date.

97 rrent methods is that shotgun proteomics has limited success at detecting many low abundance proteins

98 Current technology has limited success in the accurate detection and identifica

99 vative treatment and laser therapy both have limited success in sealing the leaks and are not as effe

100 Kinase inhibitors have limited success in cancer treatment because tumors circu

101 entifying intraintestinal fecal Stx may have limited success.

102 ntial because current treatment options have limited success in achieving durable endpoints, and anti

103 mmunoglobulin and plasmapheresis (PLEX) have limited success due to antibody rebound.

104 ocking therapeutics, current strategies have limited success in breast cancer, indicating that additi

105 at molecular and cellular levels resulted in limited success of their clinical translation.

106 and improve its reactivity, but resulted in limited success.

107 single blood sample, studies have indicated limited success using genetic and metabolomics informati

108 alone have shown little efficacy, indicating limited success in modulating neuroplasticity, especiall

109 engineered nanostructured materials has met limited success compared with that which has evolved in

110 n of these molecules in soluble form has met limited success, presumably due to their large size, het

111 man sources, such as septic systems, has met limited success.

112 multiple, simultaneous interactions has met limited success.

113 revious drug of abuse vaccines that have met limited success in the past.

114 or tumor-involved endothelial cells have met limited success.

115 ngineer new recognition specificity have met limited success.

116 eceptor-based computational methods have met limited success.

117 nels to TTX remains poor, in part because of limited success in functional expression of these channe

118 cB as a counter-selection method has been of limited success due to the presence of endogenous sacBC

119 ional one-drug-one-gene approach has been of limited success in modern drug discovery.

120 s, particularly children, which have been of limited success.

121 and motility, which has been historically of limited success in separating fertile from infertile mal

122 mTOR inhibitors are, however, of limited success.

123 Available liver support systems are still of limited success at improving survival.

124 Current smoking cessation therapies offer limited success, as relapse rates remain high.

125 They achieved only limited success as they all suffered from the high false

126 sed rechargeable batteries has achieved only limited success due to uncontrollable Li dendrite growth

127 ic approach, but thus far have achieved only limited success in the clinic.

128 ased immunohistochemistry have achieved only limited success.

129 However, there has been only limited success in developing cold-hardy cultivars.

130 treatments have been tested in ASD, but only limited success has been achieved.

131 So far there exists only limited success of attaining both strength and toughness

132 es where chemical techniques have found only limited success is biofouling of feed channels in high-p

133 maging for diagnosis, however, have had only limited success in diagnosing patients who are independe

134 ever, gene expression profiling has had only limited success in identifying therapeutic targets.

135 sult, machine learning methods have had only limited success in predicting many traits from microbiom

136 des with unusual stoichiometry have had only limited success in spite of several theoretical predicti

137 dia and enhanced consent forms have had only limited success.

138 rials used for adhesion prevention have only limited success.

139 However, only limited success has been achieved in clinical applicatio

140 sign cross-reactive trimers resulted in only limited success.

141 Until now, only limited success has been achieved in controlling pollen

142 eutic intervention often leads to no or only limited success.

143 mportant classes of conjugated polymer, only limited success has been achieved to date using block co

144 s targeting immunological pathways show only limited success.

145 nsic to glioma cells have translated to only limited success; effective therapeutic strategies will n

146 as an antiangiogenic agent has met with only limited success in the treatment of malignant gliomas.

147 ly developed for therapeutic uses, with only limited success to date.

148 tabolic strategies have so far met with only limited success, although recent findings, in particular

149 s, although these systems have met with only limited success.

150 s with chronic heart failure (HF), with only limited success.

151 ials in hope of circumventing MDR, with only limited success.

152 to reverse HIV latency but have yielded only limited success.

153 the mechanisms underlying neuropathic pain, limited success in therapeutic approaches have been atta

154 Given the previously limited success in enhancing siRNA potency with chemical

155 all of the efforts so far have only produced limited success.

156 ferent modalities, they have achieved rather limited success for other parts of the body.

157 Strategies that have received limited success in the treatment of ischemic injury, whi

158 phore engineering for fluorescence recovery, limited success has been achieved for structurally uncon

159 st few years, but their application has seen limited success beyond a few tractable species and tissu

160 unotherapeutic approaches thus far have seen limited success in PDAC due to a poorly immunogenic and

161 n delivered to the subretinal space but show limited success when delivered to the vitreous due to th

162 on studies in frontotemporal dementia showed limited success in identifying associated loci.

163 linical trials with imatinib mesylate showed limited success due to normal tissue toxicity.

164 e current immunosuppressive therapies showed limited success in maintaining long-term islet survival

165 ing of cytotoxic agents to a tumor has shown limited success by difficulties in identifying the appro

166 Protein-in-adjuvant vaccines have shown limited success against difficult diseases such as blood

167 simplified fragmentation patterns have shown limited success for the de novo sequencing of multiply c

168 eatments targeting NMDAR subtypes have shown limited success in treating patients, highlighting a nee

169 r, they are still time-consuming, have shown limited success, and are not compatible with the needs o

170 a means of enzyme replacement and have shown limited success.

171 herapeutic inhibition of PI3K has only shown limited success in clinical trials.

172 ver, biological therapies have achieved some limited success.

173 ntagonist began several years ago, with some limited success.

174 a decade ago but has not met with more than limited success in a few isolated instances.

175 The limited success in predicting siRNA potency being report

176 The limited success in understanding the pathophysiology of

177 The limited success of cancer immunotherapy is often attribu

178 The limited success of this approach, together with the reco

179 The limited success seen in cancer immunotherapy signifies t

180 The limited success with free antisense ONs in hematologic m

181 tibiotic-resistant bacterial strains and the limited success of currently available pharmaceuticals u

182 lored region of the CNS may help explain the limited success of previous brain-directed therapies.

183 These results may explain the limited success reported thus far from clinical trials o

184 sizes was observed, possibly explaining the limited success of bioinformatics in identifying regulat

185 s do not express CD20, likely explaining the limited success of this approach.

186 One hypothesis for the limited success of cloning via SCNT (1%-5%) is that the

187 adherence, which is likely critical for the limited success of most weight-loss treatments in the lo

188 One of the principal reasons for the limited success of therapeutic vaccination is that virus

189 Given the limited success of traditional methods for producing clu

190 of knowledge is particularly notable in the limited success of vectors for the delivery of combinati

191 In view of the limited success obtained with other treatments in this m

192 in a major clinical challenge because of the limited success of existing therapies.

193 usually offered at the refractory stage, the limited success rate of glaucoma drainage implant in ter

194 curable disease for many patients due to the limited success of targeted and immunotherapies.

195 term systemic corticosteroids, despite their limited success, high recurrence rate, and incidence of

196 ntially significant contributor towards this limited success rate is an incomplete knowledge of the e

197 membrane-bound peptides, there has been very limited success in achieving alignment for functional me

198 (MCI) as a prodrome for AD has also had very limited success.

199 computational algorithms typically have very limited success in genome-scale studies.

200 MHC class I-restricted T cells, has met very limited success with class II peptide-MHC complex tetram

201 ntal impact, but these efforts have met very limited success.

202 ol of protein pharmaceuticals, met with very limited success in detection and characterization of con

203 C16-targeted therapy, but have met with very limited success.

204 large polymeric molecules has proven viable, limited success was reached for smaller multivalent comp

205 e or gene sets have been proposed, there was limited success in developing methods for differential i

206 l (ENaC) blocker, has been administered with limited success as aerosol therapy for improving pulmona

207 has been demonstrated in vitro, albeit with limited success in vivo.

208 stent atrial fibrillation is associated with limited success rates and often requires multiple proced

209 ansgenic approaches have been attempted with limited success.

210 productivity at each step and attempts, with limited success, to put each in the context of an entire

211 a in an effort to achieve this goal but with limited success.

212 cally, they have shown some promise but with limited success.

213 nts used self-management strategies but with limited success.

214 technology and surgical techniques, but with limited success.

215 e efficacy of existing antibiotics, but with limited success.

216 ally focused on MET-expressing cancers, with limited success.

217 hose that have been tried in the clinic with limited success and those currently under clinical devel

218 and minor actinides (that is, Am, Cm), with limited success.

219 biodegradable polymers, and composites with limited success.

220 tion efforts focus on mosquito control, with limited success.

221 growth have been attempted for decades with limited success.

222 ug-delivery systems have been developed with limited success for tumor chemo-photothermal therapy.

223 d antibody therapy, have been developed with limited success.

224 are used to contain anthracnose disease with limited success.

225 , treatment proceeds by trial and error with limited success, probably due to the presence of multipl

226 ating the mechanisms of hepatotoxicity, with limited success in advancing therapeutic strategies.

227 to improve thiopurine therapy, however with limited success.

228 omotes and enhances anti-tumor immunity with limited success on large tumors in mice.

229 erential susceptibility have been made, with limited success.

230 , effectiveness in cell culture has met with limited success and seems to be cell-dependent.

231 and expansion of HSCs in vitro has met with limited success because of incomplete knowledge regardin

232 ity for a specific target have been met with limited success because of the structural sensitivity of

233 rsion origin(s) and pathway(s) have met with limited success due to the patchiness of available data.

234 gs, its applicability to humans has met with limited success largely due to inefficient systemic deli

235 wever, these strategies have either met with limited success or cannot be readily extended to other l

236 ith new targets, these efforts have met with limited success since the early 1960s.

237 ng recyclable systems have thus far met with limited success, as general and versatile platforms are

238 devastating disease has so far been met with limited success, but emerging knowledge of neuroscience

239 nd non-pharmacologic therapies have met with limited success, in part due to an incomplete understand

240 These approaches have met with limited success, in part due to development of resistanc

241 ever, FLT3 inhibitors have thus far met with limited success, inducing only a clearance of peripheral

242 ck the emergence of resistance have met with limited success, largely because the mechanisms underlyi

243 r immunosuppression withdrawal have met with limited success, perhaps because they measure events dow

244 idiotype or tumor lysate, have been met with limited success, probably in part due to insufficient cr

245 enes for bipolar disorder (BD) have met with limited success, which has generally been attributed to

246 nal approaches in bulk solution has met with limited success.

247 ng for N-nitrosamine formation have met with limited success.

248 C virus (HCV) in cell culture have met with limited success.

249 leukemia is an active area, but has met with limited success.

250 te self-sustaining populations have met with limited success.

251 apeutic options exist and have been met with limited success.

252 o define subtypes behaviorally have met with limited success.

253 ching the catalytic reactivity, has met with limited success.

254 ajor depressive disorder (MDD) have met with limited success.

255 ectures-as opposed to polymers-have met with limited success.

256 e this success to solid tumors have met with limited success.

257 susceptibility genes have thus far met with limited success.

258 ancer therapy has historically been met with limited success.

259 munogens bearing MPER epitopes have met with limited success.

260 es of DNA-histone interactions have met with limited success.

261 ameworks, and organic polymers have met with limited success.

262 ADPglucose pyrophosphorylase, have met with limited success.

263 onversion efficiency have, however, met with limited success.

264 precise genetic contributions have met with limited success.

265 (HIV-1) vaccine antigens have been met with limited success.

266 vailable and current therapies have met with limited success.

267 such as common human diseases have met with limited success.

268 ls, specifically, in vivo in humans met with limited success.

269 iotic polymerization reactions have met with limited success.

270 e system of the intact organism has met with limited success.

271 ogenitor cells (HPCs) in vitro have met with limited success.

272 same protocol to N-farnesyl lactams met with limited success.

273 e region of the solar spectrum have met with limited success.

274 unately, such methods have thus far met with limited success.

275 -targeted small molecule probes has met with limited success.

276 hies with pharmacologic agents have met with limited success.

277 by modifying it in various ways has met with limited success.

278 tments and surgical modalities have met with limited success.

279 s to better classify a disease have met with limited success.

280 c ductal adenocarcinoma (PDAC) have met with limited success.

281 ) of grey matter has been used for MTLE with limited success.

282 in relapsed/refractory multiple myeloma with limited success.

283 tropic and reducing agents, quite often with limited success.

284 oantigens have, in most cases, met only with limited success.

285 n beta-thalassemia patient populations, with limited success in some cases, no universally effective

286 research focused on disease prevention, with limited success.

287 mall-molecule ligands has been rewarded with limited success.

288 SF6, once with air) over a week's span with limited success at re-attaching the DM.

289 for orthologous genes in other species with limited success.

290 e aimed to improve the kinetics of SrtA with limited success.

291 in both animals and humans are underway with limited success to date.

292 undance, DNA microarrays have been used with limited success to identify regulatory transcription fac

293 the impact of pod shatter on crop yield with limited success.

294 e methanol and liquid fuels in industry, yet limited success has been made to develop clean syngas pr

295 Currently available therapies yield limited success in treating such pain, suggesting the ne

296 t models for HF hospitalization have yielded limited success and have little ability to prevent early

297 in hexagonal boron nitride(10), have yielded limited success at room temperature.

298 amos National Laboratory (LANL) have yielded limited success in vaccine trials.

299 all-trans retinoic acid (ATRA) have yielded limited success, partially due to the epigenetic silenci

300 ing porous carbons to entrap PS have yielded limited success.